Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06833008 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

StatusActive, Not Recruiting
PhasePhase 1/2
SponsorIpsen
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Final enrollment: 42 participants (planned 85) · Primary and study completion moved earlier from Oct 3, 2028 to Apr 4, 2028 · Eligibility criteria expanded, about 11 words · 2 more Show 5 more changesShow less
    • Final enrollment: 42 participants (planned 85)
    • Primary and study completion moved earlier from Oct 3, 2028 to Apr 4, 2028
    • Eligibility criteria expanded, about 11 words
    • Site details revised at 13 of 13 sites
    • Study description expanded, about 2 words
  2. 7 versions Re-verified since Feb 25, 2026, no change to tracked fieldsv15-v21
  3. Site details revised at 1 of 13 sitesv14
  4. Site details revised at 1 of 13 sitesv13
  5. Site details revised at 1 of 13 sitesv12
Show 10 earlier versionsHide 10 earlier versions
  1. 3 versions Re-verified since Aug 27, 2025, no change to tracked fieldsv9-v11
  2. Site details revised at 2 of 13 sitesv8
  3. Site details revised at 3 of 13 sitesv7
  4. Site details revised at 1 of 13 sitesv6
  5. Site details revised at 1 of 13 sitesv5
  6. Site details revised at 2 of 13 sitesv4
  7. Start date: Feb 11, 2025 to Mar 14, 2025 Study sites: 9 to 13v3 Show 1 more changeShow less
    • Study sites: 9 to 13
  8. Study sites: 1 to 9v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ipsen
46 trials monitored
See 4 trials at risk
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body.
Trial Details
NCT Number NCT06833008
Lead Sponsor Ipsen
Conditions Advanced Solid Tumor
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov